Subject(s)
Antineoplastic Agents/toxicity , Choline/analogs & derivatives , Phospholipid Ethers/toxicity , Phosphorylcholine/analogs & derivatives , Animals , Antineoplastic Agents/therapeutic use , Dogs , Female , Male , Neoplasms, Experimental/drug therapy , Phospholipid Ethers/therapeutic use , Phosphorylcholine/therapeutic use , Phosphorylcholine/toxicity , RatsABSTRACT
The study reports on the investigation of acute and subacute toxicity and on antineoplastic activity of hexadecylphosphocholine (HPC), the first compound of a new class of antineoplastic chemotherapeutics. In rats, the LD50 of HPC was 606 mumol/kg; the maximum tolerable dose over four weeks was 39 mumol/kg. Symptoms of toxicity were enteritis, spider cell activation in the liver, hemosiderosis in the spleen and reversible transaminase increase. The best therapeutic effect was observed on methylnitrosourea (MNU)-induced mammary carcinoma in the rat. Two transplantable mammary carcinomas in the rat and autochthonous benzo(a)pyrene-induced sarcomas exhibited low-grade sensitivity to HPC. The MXT mammary carcinoma of the mouse, the Walker 256 carcinosarcoma of the rat, and autochthonous acetoxymethylmethylnitrosamine-induced colonic tumors of the rat were not chemosensitive to HPC.
